Business Wire

Kindeva Global Health Security Donates ATNAA to Ukraine Through the European Commission's rescEU and Governmental Strategic Reserves Agency (RARS)

29.5.2024 15:00:00 EEST | Business Wire | Press release

Share

Kindeva Drug Delivery (Kindeva), a leading global health security provider of CBRN medical countermeasures, announced that it donated a supply of autoinjectors — specifically an antidotal treatment for chemical nerve agents — to Ukraine through the rescEU reserve of the EU Civil Protection Mechanism to aid civilians affected by the war in Ukraine.1 Medical countermeasures (MCMs), such as the ATNAA (Antidote Treatment Nerve Agent Autoinjector), are instrumental in protecting the lives of civilians and military in the event of a chemical nerve agent attack.

This donation was coordinated with the European Commission, which in 2022, established an operational system under the EU Civil Protection Mechanism to channel in-kind donations from the private sector to Ukraine, Moldova, and neighboring EU countries. Via the EU Civil Protection Mechanism, the EU coordinates emergency supply items, therapeutics and medicines, medical devices, shelter items, and more from private and public companies and entities and non-EU governmental institutions that become part of the rescEU reserve to offer an additional layer of protection when disasters strike. The Governmental Strategic Reserves Agency (RARS) in Poland acts on behalf of the European Commission and rescEU to receive the donation and arrange for local transport to Ukraine.

“The rescEU reserve allows the EU to respond more quickly to medical needs caused by health crises, like the war in Ukraine,” said Kindeva’s Tom Handel, Commercial Head - Injectables & Health Security. “Meridian Medical Technologies (Meridian), which merged with Kindeva Drug Delivery in December 2022 to create a leading drug-device CDMO, is the global health security business unit of Kindeva. The company has been putting emergency care treatment options into the hands of military and civilian defenders for more than 60 years and will continue to do so as a combined organization. Kindeva is pleased we were able to work with the European Commission to donate our chemical nerve agent antidote autoinjectors to boost Ukraine’s CBRN stockpile.”

For more information about what items can be donated, visit European Civil Protection and Humanitarian Aid Operations.

About Kindeva Drug Delivery

Kindeva Drug Delivery is a global contract development and manufacturing organization focused on drug-device combination products. We develop and manufacture products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and transdermal. Our service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.

1 The delivered goods are meant for emergency aid to Ukraine and are not intended for commercial use in the EU.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holli Kroeker
+1 308-338-2358
pr@scorrmarketing.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents New Data on CASGEVY ® , Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions11.6.2026 09:01:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with the transformative profile established in adult and adolescent patients. These data were presented at the European Hematology Association (EHA) Congress and simultaneously published in the New England Journal of Medicine (NEJM). “The data presented at EHA and published in NEJM underscore the consistent, durable and transformative benefits CASGEVY can provide to people living with sickle cell disease or transfusion-dependent beta thalassemia from early in life,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Off

PUMA Brings NITRO™ to Football With the PUMA NITRO Lab in Los Angeles11.6.2026 09:00:00 EEST | Press release

Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and NITRO™'s arrival in football for the first time on a football boot. Previous editions of the NITRO™ Lab in Paris, Tokyo, and London explored the future of running performance and cemented NITRO™ as the defining technology in elite running with Fast-R3. Now, with the world’s attention turning to football, Los Angeles is where that journey takes its next step, introducing the same innovation DNA that reshaped the track to the pitch, when it matters most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610728823/en/ Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and N

AHS Properties Acquires Shangri-La Hotel for AED 1.1 Billion in Landmark Sheikh Zayed Road Transaction11.6.2026 09:00:00 EEST | Press release

AHS Properties today announced the acquisition of Shangri-La Hotel for AED 1.1 billion, one of the largest single-asset real estate transactions recorded in recent history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605096792/en/ Shangri-La Hotel Exterior, Sheikh Zayed Road. (Photo: AETOSWire) Acquired from Mismak Asset Management, the transaction cements one of the most concentrated private-sector bets on Sheikh Zayed Road's next decade. The Shangri-La Hotel is a 43-floor, 200-metre tower on Sheikh Zayed Road, and was one of the first five-star hotels to open on the corridor when it was completed in 2003. The acquisition adds an iconic anchor asset to a portfolio that already includes AHS Tower, a recently sold-out Grade-A commercial development on Sheikh Zayed Road, and AHS City, the developer’s flagship master-planned, mixed-use community on the corridor with a forecast gross development value of AED 25 billion. To

Curatis Increases Revenue Growth Guidance for 202611.6.2026 08:00:00 EEST | Press release

Curatis Holding AG (SIX: CURN) increases its revenue growth guidance for the financial year 2026: the company is forecasting a revenue growth of approximately 40% in 2026, in contrast to the previous outlook of over 25%. Based on preliminary figures for the first five months of 2026, Curatis expects a significantly higher than anticipated revenue growth for 2026. This growth is driven by products that Curatis has marketed for some time, as well as by products added to its portfolio in 2025 and 2026. Under the new guidance, Curatis projects revenues of approximately CHF 15m in 2026, up from CHF 10.8m in 2025. Curatis will publish detailed financial figures for the first six months of 2026 in the half-year report on 21 September 2026. About Curatis Curatis Holding AG is a publicly listed company (CURN.SW) focused on the late stage development and commercialization of drugs for rare diseases and specialty care. Curatis has a sales portfolio of more than 40 products and a pipeline of orpha

Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments11.6.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD) has released findings from a landmark global survey conducted across the United States (U.S.), Brazil, the United Kingdom (UK), and China – the largest of its kind – exploring the evolving expectations and experiences of patients and HCPs with anti-wrinkle aesthetic treatments. As the dermatology category leader, this survey demonstrates Galderma’s commitment to advancing progress in this market, through robust clinical research, product performance, and practitioner support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610228460/en/ Anti-wrinkle treatments are among the most established procedures in aesthetic medicine and currently represent the most commonly performed nonsurgical cosmetic treatment worldwide.2 The market is set to expand further, with 85% of surveyed patients globally indicating they plan to maintain or increase their use in the future, including 97% in China and 87% in the UK.2

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye